Sub-lobectomy vs Lobectomy in IIA-IIIB NSCLC After Neoadjuvant IO+Chemo

This study is a prospective, randomized controlled multicenter clinical trial. The study population consisted of non-small cell lung cancer（NSCLC） patients in stage IIA-IIIB (IASLC 9th edition) who received immunotherapy combined with platinum based dual drug chemotherapy before neoadjuvant therapy and were evaluated by the committee to be feasible for sub lobectomy R0 resection. After entering the study, they were randomly divided into a sub lobectomy group (study group) and a lobectomy group (control group). Follow up will be conducted after surgery. The study includes screening/baseline pe

Trial Details

NCT ID
NCT07612722
Phase
NA
Sponsor
Wen-zhao ZHONG
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Sub-lobectomy
  • Lobectomy
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Voluntarily participate in the research and sign an informed consent form;
  • Age ≥ 18 years old,\<75 years old, both male and female;
  • The physical fitness status score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 or 1;
  • Expected survival period ≥ 12 months;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →